Panelists discuss how treatment strategies differ between transplant-eligible and transplant-ineligible multiple myeloma patients, with transplant eligibility determined by functional status rather ...
The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma. The U.S.
Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...
The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) for patients with newly ...
Despite improvements in therapies, multiple myeloma (MM) is a disease that will always relapse. Why is this? What is the key to finding effective therapies to cure MM? Evan Newell, a Professor in the ...
For more information about Sylvester Comprehensive Cancer Center’s Myeloma Institute, click here or visit the UHealth Collective: When business owner Richard Dapaah suffered severe back pain while in ...
The stage of diagnosis can impact survival rates. Patients with stage III multiple myeloma (MM) have an average life expectancy of 29 months, whereas patients with stages I and II disease survive on ...
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results